How PROTACs and molecular glues work: a mechanistic comparison
PROTACs are heterobifunctional molecules built from three essential components: a target protein ligand (warhead), an E3 ubiquitin ligase recruiting ligand, and a chemical linker that bridges the two. By forming a ternary complex—target–PROTAC–E3 ligase—they position the target in proximity to the ubiquitination machinery, triggering proteasomal degradation. Critically, PROTACs function catalytically: after ubiquitination, the PROTAC is released and can recruit additional target molecules, potentially achieving potent degradation at substoichiometric concentrations.
Molecular glue degraders operate through an entirely different logic. These are monovalent, small molecules—typically below 500 Da—that bind directly to an E3 ligase and induce conformational changes or create new surface features that enable recognition of proteins not normally recognised by that ligase. These proteins, called neosubstrates, are then ubiquitinated and degraded. The defining feature is the absence of an explicit target-binding moiety: the molecular glue does not need to engage the target at all before degradation can occur.
The canonical examples are the IMiDs—thalidomide, lenalidomide, and pomalidomide—which bind to cereblon (CRBN) and create a surface that recruits zinc finger transcription factors such as IKZF1 and IKZF3. The glutarimide ring serves as the essential CRBN-binding pharmacophore, occupying a hydrophobic pocket formed by three tryptophan residues, while variable substituents modulate the neosubstrate-binding surface and determine which proteins are ultimately degraded.
In PROTACs, cooperativity—where the ternary complex (target–PROTAC–E3 ligase) is more stable than predicted from the two binary binding affinities alone—is often essential for potent degradation. A PROTAC may bind both partners individually with modest affinity yet still achieve strong degradation if the resulting ternary complex is highly stable.
PROTACs function catalytically: after ubiquitinating the target protein, the PROTAC molecule is released and can recruit additional target molecules for degradation, potentially achieving potent effects at substoichiometric concentrations.
How each modality achieves target selectivity
PROTAC selectivity is shaped by at least four overlapping mechanisms, meaning that degradation selectivity can substantially exceed the binding selectivity of the warhead alone. Even promiscuous kinase inhibitors have been converted into selective degraders through proper E3 ligase selection and linker optimisation. The primary determinants are: the warhead's intrinsic binding preference; the geometry of the resulting ternary complex; linker properties; and the choice of E3 ligase.
Ternary complex geometry is particularly powerful. Even if a PROTAC binds multiple related proteins, degradation may be selective for targets that can form geometrically favourable complexes with the recruited E3 ligase. Protein-protein interactions between the target and E3 ligase within the ternary complex contribute significantly to this selectivity. Linker length and composition can switch selectivity between closely related protein isoforms while using the same warhead and E3 ligase ligand.
"Degradation selectivity can exceed binding selectivity — a promiscuous kinase inhibitor warhead can be converted into a selective degrader through E3 ligase selection and linker optimisation alone."
Molecular glue selectivity operates through a different logic: it arises from the structural requirements for neosubstrate binding to the modified E3 ligase surface. For CRBN-based molecular glues, the neosubstrate typically requires specific structural motifs — such as β-hairpin structures with exposed glycine residues in zinc finger proteins — that can engage the glue-modified CRBN surface. Different molecular glue scaffolds create distinct surface modifications on the E3 ligase, leading to different neosubstrate profiles. For example, thalidomide, lenalidomide, and pomalidomide primarily degrade IKZF1/3; CC-885 degrades GSPT1 (a translation termination factor); and DKY709 shows distinct preferences including ZFP91.
Unlike PROTACs, molecular glues typically do not exhibit a "hook effect" — the loss of activity at high concentrations caused by disruption of ternary complex formation. This provides more predictable dose-response relationships and may simplify clinical dose selection.
Different molecular glue scaffolds binding to the same E3 ligase (cereblon) can recruit entirely different sets of neosubstrate proteins: thalidomide/lenalidomide/pomalidomide primarily degrade IKZF1/3, CC-885 degrades GSPT1, and DKY709 shows distinct neosubstrate preferences including ZFP91.
E3 ligase recruitment: repertoire, pharmacophores, and constraints
The human genome encodes more than 600 E3 ubiquitin ligases, yet fewer than 2% have been successfully exploited for PROTACs. The field is dominated by two: VHL (von Hippel-Lindau), recruited via hydroxyproline-containing ligands derived from HIF-1α peptide mimetics, and cereblon (CRBN), recruited via phthalimide-based thalidomide derivatives. VHL-based PROTACs typically exceed 700 Da in molecular weight; CRBN-based PROTACs often show better cell permeability. Emerging E3 ligases including MDM2, IAP family members, DCAF15, DCAF16, RNF4, and RNF114 are under investigation, but each requires identification of suitable small-molecule ligands.
Explore the full patent landscape for PROTAC and molecular glue E3 ligase recruitment strategies in PatSnap Eureka.
Search Patent Intelligence in PatSnap Eureka →An emerging strategy involves recruiting E3 ligases with restricted tissue expression to achieve tissue-selective protein degradation, potentially reducing on-target, off-tissue toxicity. This approach leverages the uneven distribution of specific E3 ligases across cell types — a pharmacological dimension unavailable to conventional inhibitors.
For molecular glues, the picture is more concentrated. The vast majority of characterised molecular glue degraders target CRBN, driven by the clinical success of IMiDs. Beyond cereblon, two additional examples have emerged: DCAF15, recruited by aryl sulfonamides such as indisulam and E7820 to degrade RBM39; and CRL4-DDB1, recruited by cyclin-dependent kinase inhibitors to degrade cyclin K. The glutarimide pharmacophore that anchors IMiDs to CRBN's tryptophan-lined pocket has become the dominant scaffold for rational CRBN-targeting glue design, though structural biology and computational methods are beginning to enable more systematic approaches beyond this scaffold.
More than 600 E3 ligases exist in the human genome, but fewer than 2% have been successfully exploited for PROTAC-based targeted protein degradation. The field is dominated by VHL and cereblon (CRBN), with emerging ligases including MDM2, IAP family members, DCAF15, DCAF16, RNF4, and RNF114.
Which approach is superior for undruggable targets?
For targets with known small-molecule binding sites, PROTACs offer a rational, modular path to degradation. The three-component structure allows independent optimisation of target binding, E3 ligase recruitment, and linker geometry. Transcription factors such as BET family proteins (BRD2/3/4) have been successfully targeted by PROTACs with superior efficacy compared to BET inhibitors, and recent advances show PROTACs can also degrade membrane proteins and receptor tyrosine kinases — areas where molecular glues have seen limited success. Crucially, due to the catalytic mechanism and potential for positive cooperativity, PROTACs can achieve potent degradation even with low-affinity target ligands in the micromolar Kd range, provided the ternary complex is stable.
However, for truly ligand-less proteins — those lacking any known small-molecule binding site — molecular glues represent the only viable degradation strategy. They do not require pre-existing target engagement; instead, they create a binding interface on the E3 ligase that can recognise structural features of the target that would not normally be considered druggable. The clinical validation of this approach is unambiguous: lenalidomide and pomalidomide are FDA-approved drugs that degrade IKZF1/3 zinc finger transcription factors, a protein class long considered undruggable. Their β-hairpin structures with exposed glycine residues provide the recognition motif for glue-modified CRBN — a surface interaction that would be completely inaccessible to a conventional small-molecule inhibitor.
"For truly ligand-less proteins, molecular glues offer the only viable degradation strategy — they create a binding interface on the E3 ligase that can recognise structural features of the target that would not normally be druggable."
The drug-like property gap between the two modalities is substantial. PROTACs typically range from 700–1000 Da, frequently violating Lipinski's Rule of Five, which can result in poor cell permeability, limited oral bioavailability, and challenges accessing specific intracellular compartments. Molecular glues, at under 500 Da, generally exhibit better pharmacokinetic profiles. Lenalidomide and pomalidomide are orally bioavailable drugs — a benchmark that most PROTACs have yet to match. For CNS indications or other settings requiring stringent pharmacokinetic performance, this gap is clinically decisive.
The principal limitation of molecular glues is the difficulty of rational design. Without an explicit target-binding moiety, structure-based design is challenging. Discovery has been largely serendipitous, and predicting which proteins will be degraded by a new molecular glue scaffold remains difficult. Furthermore, because molecular glues can recruit multiple neosubstrates, off-target degradation is a genuine concern: IMiDs degrade both IKZF1 and IKZF3, and different IMiDs show distinct neosubstrate profiles, complicating toxicity prediction. Their E3 ligase diversity is also constrained — predominantly limited to CRBN — whereas PROTACs can theoretically utilise any E3 ligase for which a suitable ligand exists.
Analyse degrader patent filings, clinical compound landscapes, and E3 ligase IP with PatSnap Eureka's AI-powered search.
Explore Degrader Patent Data in PatSnap Eureka →Emerging hybrid approaches are beginning to blur the boundary between the two modalities. Compact PROTACs aim to reduce molecular weight through more efficient linkers and smaller E3 ligase ligands. Bifunctional molecular glues combine a weak target-binding moiety — insufficient for functional inhibition on its own — with molecular glue-like E3 ligase engagement to enhance degradation. And advances in structural biology and computational methods are enabling more rational design of molecular glues, reducing reliance on serendipitous discovery.
Molecular glues are superior for truly ligand-less undruggable targets because they do not require pre-existing small-molecule binding sites on the target protein. Their molecular weights are typically below 500 Da, offering better oral bioavailability and cell permeability compared to PROTACs, which typically range from 700–1000 Da and frequently violate Lipinski's Rule of Five.
Clinical progress, resistance mechanisms, and the road ahead
As of 2024, the clinical pipeline for targeted protein degraders spans both modalities at multiple stages. PROTACs in clinical trials include ARV-110 (targeting the androgen receptor), ARV-471 (targeting the estrogen receptor), and compounds targeting BTK and BRD4. On the molecular glue side, lenalidomide and pomalidomide are FDA-approved for multiple myeloma; iberdomide (CC-220) has reached Phase III; mezigdomide (CC-92480) is in Phase II; and DKY709 is in Phase I. The clinical validation of orally bioavailable molecular glues like lenalidomide and pomalidomide demonstrates that this modality can clear the full regulatory and pharmacokinetic hurdles of drug development, according to FDA approvals.
Both modalities face overlapping resistance mechanisms: mutations in E3 ligase components, downregulation of E3 ligase expression, alterations in ubiquitin-proteasome system components, and target protein mutations affecting degrader binding. The broader E3 ligase repertoire — and tissue-specific approaches that leverage E3 ligases with restricted expression — may mitigate these concerns. Expanding beyond VHL and CRBN is therefore not merely a question of pharmacological breadth but a resistance-mitigation strategy, as noted in studies published by Nature.
Future directions identified in the literature include: machine learning and molecular dynamics simulations to predict ternary complex formation and optimise degrader design; systematic identification of ligands for additional E3 ligases to expand the toolkit for both modalities; incorporation of subcellular localisation signals to enable compartment-specific protein degradation; and combination strategies pairing degraders with immunotherapies, chemotherapies, and other targeted agents. Standards bodies such as ISO are also beginning to address assay standardisation for degrader characterisation, while the NIH has funded targeted protein degradation as a priority research area through its National Center for Advancing Translational Sciences. Comprehensive patent intelligence available through PatSnap's life sciences platform tracks filings across all these emerging directions in real time.